Jian Qin Lin

US Patent:

7919519, Apr 5, 2011

Filed:

Mar 21, 2007

Appl. No.:

11/726351

Inventors:

Roland Burli - Pasadena CA, US
Victor J. Cee - Thousand Oaks CA, US
Jennifer Golden - Simi Valley CA, US
Brian Alan Lanman - Oak Park CA, US
Susana Neira - Thousand Oaks CA, US
Ashis Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Xiang Yu - Acton MA, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Bolton MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Washington DC, US
Robert C. Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mevaseret Zion, IL
Zhaoda Zhang - Andover MA, US

Assignee:

Epix Pharmaceuticals Inc. - Lexington MA

International Classification:

A61K 31/404
A61K 31/381
A61K 31/343
C07D 209/12
C07D 333/56
C07D 307/80

US Classification:

514419, 514443, 514469, 548494, 549 58, 549469

Abstract:

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e. g. , for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

US Patent:

20110212940, Sep 1, 2011

Filed:

Feb 25, 2011

Appl. No.:

13/034895

Inventors:

Roland Burli - Pasadena CA, US
Victor J. Cee - Thousand Oaks CA, US
Jennifer Golden - Simi Valley CA, US
Brian Alan Lanman - Oak Park CA, US
Susana Neira - Thousand Oaks CA, US
Ashis Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Xiang Yu - Acton MA, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Bolton MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Washington DC, US
Robert C. Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mavaseret Zion, IL
Zhaoda Zhang - Andover MA, US

Assignee:

EPIX PHARMACEUTICALS, INC. - Lexington MA

International Classification:

A61K 31/397
C07D 405/10
A61K 31/4525
C07D 405/14
A61K 31/443
C07D 413/14
A61K 31/427
C07D 409/14
A61K 31/4725
A61K 31/4025
C07D 307/80
A61K 31/343
A61K 31/5377
C07D 413/10
A61K 31/41
A61P 35/00
A61P 37/06
A61P 29/00
A61P 3/10
A61P 25/00
A61P 17/06
A61P 35/02
A61P 11/00
A61P 11/06
A61P 17/02
A61P 9/00
A61P 9/10
A61P 13/12
A61P 1/16
A61P 7/06

US Classification:

51421018, 548953, 546196, 5462841, 548205, 546147, 514307, 548525, 514422, 549469, 514469, 544111, 544153, 5142335, 548252, 5142102

Abstract:

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.